Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer (LucaVax)

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified April 2012 by Kael-GemVax Co., Ltd.
Sponsor:
Collaborator:
Quintiles
Information provided by (Responsible Party):
Kael-GemVax Co., Ltd.
ClinicalTrials.gov Identifier:
NCT01579188
First received: April 13, 2012
Last updated: April 18, 2012
Last verified: April 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is not yet open for participant recruitment.
  Estimated Study Completion Date: May 2016
  Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)